Immucor claimed that NEO is designed to increase productivity, performance and flexibility of high volume laboratories. NEO delivers type-and-screen throughput and broadest test menu as well as new STAT priority functionality for improved workflow.
Gioacchino De Chirico, president and chief executive officer of Immucor, said: “We believe there is a significant market opportunity for NEO and we are very excited about achieving 510(k) clearance from the FDA. NEO is the most recent example of Immucor’s commitment to deliver products that improve patient safety and the practice of transfusion medicine.”
Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion.
Immucor markets a complete family of automated instrumentation for all of its market segments. The company’s automation strategy provides scalable solutions to meet the needs of all blood banks, regardless of size.
